ClinicalTrials.gg
Not yet recruitingNCT06882915Updated Jun 8, 2026

Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study

A Phase 1 interventional study of Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab in Colorectal Cancer (CRC), sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University — 19 open to participants now, 20 under way, 2 of them phase 3. Colorectal Neoplasms · Second Affiliated Hospital, School of Medicine, Zhejiang University.

Planned enrollment
21st of 24
20 · median 46
Started
2026
with 4 others
Phase 1
4 of 32
4 open now
Primary completion
2027-05
later than 12 of 19 live
Registered
25th of 32
by date

Among the 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 12 of the 19 other live ones, and was the 25th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

19 of the 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University, or all of them as a file.
02

Study summary

Colorectal cancer (CRC) is one of the most common malignant tumors. With the rapid development of China's economy, people's living standards have been significantly improved, and lifestyles and dietary structures have changed. Smoking, drinking, high-fat, high-energy diets, etc. have led to an increase in the incidence of colorectal cancer year by year. Data show that in 2022, there will be 510,000 new cases of colorectal cancer in China, and about 240,000 deaths related to colorectal cancer. Radical surgery is the main initial treatment for early and middle-stage colorectal cancer and some metastatic colorectal cancer. Although the level of surgical treatment of colorectal cancer has been greatly improved and can achieve cure for some patients, its 5-year overall survival rate is only about 60%, and the main cause of death is distant metastasis and recurrence. In recent years, with the in-depth understanding of the treatment mechanism of metastatic colorectal cancer (mCRC), a variety of new treatment options have been proposed and applied in clinical practice in order to improve the quality of life of patients and prolong their survival.

Trifluridine/tipivirine (TAS-102) is a new type of cytotoxic drug that exerts anti-tumor effects by directly incorporating into DNA chains to destroy DNA function. Its mechanism of action is different from that of fluorouracil drugs, and it can resist 5-fluorouracil (5-FU) resistance, providing a new treatment option for mCRC patients. TAS-102 has been approved in China for mCRC patients who have previously received fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, as well as those who have previously received or are not suitable for anti-vascular endothelial growth factor (VEGF) therapy and anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). Bevacizumab, as a monoclonal antibody targeting VEGF, exerts its anti-tumor effect by inhibiting tumor angiogenesis. Putlimumab, as an immune checkpoint inhibitor, enhances the body's immune response to tumors by blocking the PD-1/PD-L1 signaling pathway.

Combination therapy has attracted much attention due to its possible synergistic effect. Studies have shown that TAS-102 combined with bevacizumab can achieve longer overall survival (OS) than TAS-102 monotherapy. In addition, TAS-102 combined with bevacizumab for refractory mCRC has also been approved by the FDA, showing its potential and importance in the treatment of mCRC. Therefore, this study aims to explore the efficacy and safety of TAS-102 combined with bevacizumab and putelimab in patients with mCRC after cytoreductive surgery, in order to provide a more effective treatment for mCRC patients. Through the design of a single-arm, single-center clinical study, we can have a deeper understanding of the efficacy and safety of this combined treatment in a specific patient population, providing a scientific basis for future clinical applications.

03

Conditions studied

  • Colorectal Cancer (CRC)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who had undergone cytoreductive surgery (CC0-1) for colorectal cancer with peritoneal ;
  2. Patients with extra-peritoneal metastatic lesions that were unlikely to affect prognosis in the short term;
  3. Patients who had failed standard therapies (disease progression or intolerance to oxaliplatin, irinotecan, fluorouracil, or other chemotherapeutic agents) or for whom no effective treatment options were available;
  4. Patients with histologically and radiologically confirmed peritoneal metastasis from colorectal cancer, with microsatellite stable (MSS) status as determined by genetic testing;
  5. Age ≥ 18 years at the time of ;
  6. Estimated > 6 months;
  7. (ECOG) performance status of 0 or 1;
  8. Adequate function of major organs (cardiac, hepatic, and renal);
  9. Adequate hematological parameters: (ANC) ≥ 1.5 × 10⁹/L, white blood cell count (WBC) ≥ 3.0 × 10⁹/L, ≥ 10 g/dL, and count ≥ 100 × 10⁹/L;
  10. Adequate biochemical parameters: total ≤ 1.5 × (ULN); (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; serum creatinine and blood urea nitrogen (BUN) ≤ 1.5 × ULN;
  11. Ability to comply with the study protocol and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  1. Refusal to provide ;
  2. Currently participating in an interventional clinical study, or having received other drugs or devices within 4 weeks prior to enrollment;
  3. Concurrent , except for malignancies that have been clinically cured;
  4. Other severe diseases that, in the investigator's judgment, may affect follow-up compliance or short-term survival;
  5. Known to any component of TAS-102, bevacizumab, or serplulimab;
  6. Uncontrolled ;
  7. Active disease;
  8. Pregnant or lactating women;
  9. History of psychiatric disorders;
  10. Uncontrolled comorbidities including, but not limited to, active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, severe coronary artery disease, or cerebrovascular disease, or any other condition deemed by the investigator to render the patient ineligible for enrollment;
  11. Any other condition that the investigator considers unsuitable for enrollment.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Trifluridine/tipiracil (TAS-102) combined with bevacizumab and serplulimab

    The treatment regimen consisted of trifluridine/tipiracil (TAS-102) combined with bevacizumab and serplulimab, administered in 14-day cycles. TAS-102: Administered at the recommended dose of 35 mg/m² twice daily with meals, on Days 1-5 of each 14-day cycle, followed by a treatment-free interval from Days 9-14. Bevacizumab: Administered intravenously at the recommended dose of 5 mg/kg per infusion, as prescribed, once every 14 days. Serplulimab: Administered intravenously at the recommended dose of 100 mg per infusion over 30 minutes, once every 14 days.

    Drug: Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab

Interventions

  • DrugTrifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab

    TAS-102: Use at the recommended dose of 35 mg/m² each time, twice a day on the 1st to 5th day and the 8th to 12th day every 28 days, with meals. Bevacizumab: Once a day on the 1st and 15th day every 28 days, at the recommended dose of 5 mg/kg each time, with meals. Putlimumab: At the recommended dose of 200 mg/time, intravenous drip, infusion time is 60 minutes, once every 28 days.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    The period from the beginning of treatment to the first occurrence of disease progression or death from any cause. If such situation is not met, the last evaluation date shall be used for analysis. In addition, if the treatment is terminated without confirming the progress of the disease, the imaging examination and follow-up should also be carried out after the treatment is terminated.

    Time frame: Two Years

Secondary outcomes

  1. Objective Remission Rate (ORR)

    The proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time limit. The remission period usually refers to the period from the beginning of curative effect to the confirmation of tumor progression. The objective response rate is generally defined as the sum of complete response plus partial response (CR+PR).

    Time frame: Two Years

  2. Overall Survival (OS)

    The time from the date of treatment to the date of death due to any reason. For patients who survived in the final analysis, the date of the last contact will be recorded.

    Time frame: Two Years

  3. Treatment response

    To evaluate tumor response using imaging examinations (CT/MRI) and tumor shrinkage rate using the response evaluation criteria in solid tumors (RECIST 1.1).

    Time frame: Two Years

  4. Incidence rate of adverse events

    According to NCI CTCAE v5.0

    Time frame: Baseline before any treatment,3 months after any treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2027, 10 months later.

Of 166 non-industry phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 74. This study's planned 10 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 19, 2025
StartEst.
Jun 6, 2026
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06882915
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Jun 6, 2026 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jun 8, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion